AccScience Publishing / ARNM / Online First / DOI: 10.36922/arnm.3391
Submit to ARNM
Cite this article
12
Download
254
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Efficacy and safety of stereotactic radiotherapy in oligometastases

Huan Dong1† ,  Rong Li1,2† ,  He-Qing Huang1 ,  Xing-Hua Chen1 ,  Zi-Yan Zhou3 ,  Min Kang1*
Show Less
1 Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Radiation Oncology Clinical Medical Research Center of Guangxi, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China
2 Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
3 Key Laboratory of Early Prevention and Treatment for Regional High-Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning, Guangxi Zhuang Autonomous Region, China
ARNM 2024, 2(4), 3391 https://doi.org/10.36922/arnm.3391
Submitted: 9 April 2024 | Accepted: 28 June 2024 | Published: 13 November 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Distant metastasis remains a leading cause of treatment failure in patients with cancer. While salvage treatments such as surgery, targeted therapy, and immunotherapy provide some benefits, they have inherent limitations. This study examines the efficacy and safety of stereotactic radiotherapy (SRT) in managing oligometastatic tumors. We retrospectively analyzed data from 96 patients with oligometastatic tumors who were treated with SRT at the Department of Radiotherapy of the First Affiliated Hospital of Guangxi Medical University between September 2019 and March 2023. Descriptive statistics were used to analyze patient characteristics, tumor response, and survival outcomes, whereas a single-sample ratio test was used to compare SRT efficacy across different tumor sites. Kaplan–Meier analysis was used to determine progression-free survival (PFS) and overall survival (OS). Three months post-treatment, the complete response, partial response, stable disease, and progressive disease rates were 26.32%, 50.00%, 21.05%, and 2.63% for liver oligometastases; 0.00%, 39.13%, 43.48%, and 17.39% for lung oligometastases; and 8.57%, 62.86%, 25.71%, and 2.86% for brain oligometastases, respectively. The objective response rate was 65.62%, and the disease control rate was 93.75%. The median PFS was 18 months, and the median OS was 27 months. The primary lesions were mainly located in the liver and lungs. Compared with previous studies where stereotactic ablative body radiotherapy achieved a median OS of 16 months for liver metastases and surgery yielded an OS of 7 – 24 months for non-small cell lung cancer with brain metastases, our SRT outcomes were significantly improved. Adverse events (≥grade 3), primarily hematological toxicity, occurred in only 5.21% of patients. SRT was both effective and well-tolerated among patients with oligometastatic tumors, offering a promising treatment option.

Keywords
Stereotactic radiotherapy
Oligometastases
Efficacy
Safety
Funding
This work was supported by grants from the National Natural Science Foundation of China (grant numbers 82272736 and 82160467); the Research Foundation of the Science and Technology Department of Guangxi Province, China (grant number 2023GXNSFDA026009); the Research Foundation of the Health Department of Guangxi Province, China (grant number S2018087); the Autonomous Region Health Commission Self-funded Research Project (grant number Z-A20230472); and the local science and technology development projects organized under the guidance of the central government (grant number ZY18057006).
Conflict of interest
The authors declare they have no competing interests.
References
  1. Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: Optimal number of treatment cycles. Expert Rev Anticancer Ther. 2016;16(6):653-660. doi: 10.1586/14737140.2016.1170596

 

  1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.doi: 10.1056/NEJMoa0708857

 

  1. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: A review. JAMA. 2021;325(7):669-685. doi: 10.1001/jama.2021.0106

 

  1. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188-196. doi: 10.1016/j.ejphar.2018.07.034

 

  1. Li B, Chan HL, Chen P. Immune checkpoint inhibitors: Basics and challenges. Curr Med Chem. 2019;26(17):3009-3025. doi: 10.2174/0929867324666170804143706

 

  1. Molla M, Fernandez-Plana J, Albiol S, et al. Limited liver or lung colorectal cancer metastases. systemic treatment, surgery, ablation or SBRT. J Clin Med. 2021;10(10):2131. doi: 10.3390/jcm10102131

 

  1. Abel S, Lee S, Ludmir EB, Verma V. Principles and applications of stereotactic radiosurgery and stereotactic body radiation therapy. Hematol Oncol Clin North Am. 2019;33(6):977-987. doi: 10.1016/j.hoc.2019.08.007

 

  1. Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer. 2018;124(4):667-678. doi: 10.1002/cncr.31196

 

  1. Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S. The current role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Cancers (Basel). 2022;14(18):4383. doi: 10.3390/cancers14184383

 

  1. Myrehaug S, Sahgal A, Russo SM, et al. Stereotactic body radiotherapy for pancreatic cancer: Recent progress and future directions. Expert Rev Anticancer Ther. 2016;16(5):523-530. doi: 10.1586/14737140.2016.1168698

 

  1. Haque W, Butler EB, Teh BS. Stereotactic body radiation therapy for prostate cancer-a review. Chin Clin Oncol. 2017;6(Suppl 2):S10. doi: 10.21037/cco.2017.06.05

 

  1. Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cárdenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6(2):86-95. doi: 10.1016/j.prro.2015.10.011

 

  1. Sogono P, Bressel M, David S, et al. Safety, efficacy, and patterns of failure after Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for oligometastases. Int J Radiat Oncol Biol Phys. 2021;109(3):756-763. doi: 10.1016/j.ijrobp.2020.10.011

 

  1. Dunne EM, Fraser IM, Liu M. Stereotactic body radiation therapy for lung, spine and oligometastatic disease: Current evidence and future directions. Ann Transl Med. 2018;6(14):283. doi: 10.21037/atm.2018.06.40

 

  1. Siddiqui F, Patel M, Khan M, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2009;74(4):1047-1053. doi: 10.1016/j.ijrobp.2008.09.022

 

  1. Hsieh RW, Borson S, Tsagianni A, Zandberg DP. Immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2021;11:705614. doi: 10.3389/fonc.2021.705614

 

  1. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15(8):1179-1186. doi: 10.1093/annonc/mdh308

 

  1. Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: Concurrent re-irradiation and chemotherapy, or chemotherapy alone. J Clin Oncol. 2006;24(17):2653-2658. doi: 10.1200/JCO.2005.05.3850

 

  1. Yokota T, Homma A, Kiyota N, et al. Immunotherapy for squamous cell carcinoma of the head and neck. Jpn J Clin Oncol. 2020;50(10):1089-1096. doi: 10.1093/jjco/hyaa139

 

  1. Chen L, Mo DC, Hu M, Zhao SJ, Yang QW, Huang ZL. PD-1/ PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis. Am J Otolaryngol. 2022;43(2):103324. doi: 10.1016/j.amjoto.2021.103324

 

  1. Lau A, Yang WF, Li KY, Su YX. Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma- a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;153:102984. doi: 10.1016/j.critrevonc.2020.102984

 

  1. Moskovitz J, Moy J, Ferris RL. Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol Rep. 2018;20(2):22. doi: 10.1007/s11912-018-0654-5

 

  1. Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer. 2010;69(3):251-258. doi: 10.1016/j.lungcan.2010.05.003

 

  1. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg. 2001;122(3):548-553. doi: 10.1067/mtc.2001.116201

 

  1. Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases. Clin Colon Rectal Surg. 2009;22(4):225-232. doi: 10.1055/s-0029-1242462

 

  1. Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol. 2011;2011:285840. doi: 10.1155/2011/285840

 

  1. Liu E, Stenmark MH, Schipper MJ, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol. 2013;6(4):442-446. doi: 10.1593/tlo.12448

 

  1. Mantel F, Glatz S, Toussaint A, Flentje M, Guckenberger M. Long-term safety and efficacy of fractionated stereotactic body radiation therapy for spinal metastases. Strahlenther Onkol. 2014;190(12):1141-1148. doi: 10.1007/s00066-014-0706-1

 

  1. Zhao X, Zhu X, Fei J, et al. Short-term outcomes and clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) in treatment of adrenal gland metastases from lung cancer. Radiat Oncol. 2018;13(1):205. doi: 10.1186/s13014-018-1152-5

 

  1. Villaruz LC, Kubicek GJ, Socinski MA. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep. 2012;14(4):333-341. doi: 10.1007/s11912-012-0240-1

 

  1. Kim TH, Nam TK, Yoon SM, Kim TH, Choi YM, Seong J. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: A multi-institutional retrospective study (KROG 20-04). Cancers (Basel). 2022;14(23):5848. doi: 10.3390/cancers14235848

 

  1. Schiff D, Messersmith H, Brastianos PK, et al. Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline. J Clin Oncol. 2022;40(20):2271-2276. doi: 10.1200/JCO.22.00333

 

  1. Niranjan A, Monaco E, Flickinger J, Lunsford LD. Guidelines for multiple brain metastases radiosurgery. Prog Neurol Surg. 2019;34:100-109. doi: 10.1159/000493055
Share
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept